Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:37:18 2024-04-29 am EDT			After market 03:01:24 pm
3.466 ^EUR	+0.64%		3.434	-0.92%

Apr. 11	Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	CF
Mar. 26	Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	MT

Valneva: Deep Track Biotechnology Master holds less than 5% of the capital

April 11, 2024 at 07:02 am EDT

On April 10, 2024, Deep Track Biotechnology Master Fund declared to the AMF that it had crossed below the threshold of 5% of the capital of Valneva SE and held 6,925,000 Valneva SE shares representing the same number of voting rights, i.e. 4.97% of the capital and 4.34% of the voting rights of this company.

This threshold crossing results from the sale of Valneva SE shares on the market.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Valneva

Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	Apr. 11	CF
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	Mar. 26	MT
Valneva: Phase 1 trial initiated in the Zika virus	Mar. 26	CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	Mar. 26	CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129%	Mar. 20	DJ
Valneva SE Raises Revenue Guidance for 2024	Mar. 20	CI
Valneva SE Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Transcript : Valneva SE, 2023 Earnings Call, Mar 20, 2024	Mar. 20
Valneva: share price down, forecasts below expectations	Mar. 20	CF
French biotech company Valneva raises product sales guidance	Mar. 20	RE
Valneva: first loan repayment postponed	Mar. 18	CF
Valneva Secures 18-month Extension to Interest-only Period for US Debt Facility	Mar. 18	MT
Valneva: the Grimaud family group below 15% of voting rights	Mar. 05	CF
U.S. CDC Advisory Committee Recommends Use of Valneva?s Single-Dose Chikungunya Vaccine IXCHIQ	Feb. 29	CI
Valneva: Ixchiq vaccine recommended by ACIP	Feb. 29	CF
US Centers for Disease Control's Committee Recommends Valneva's Chikungunya Virus Vaccine	Feb. 29	MT
Valneva SE Announces Revenue Results for Full Year 2023	Feb. 15	CI
Valneva Se Announces Earnings Guidance for 2024	Feb. 15	CI
Valneva: 26% increase in product sales in 2023	Feb. 15	CF
VALNEVA : Oddo BHF confirms its recommendation on the stock	Feb. 05	CF
Valneva Sells Tropical Disease Priority Review Voucher for $103 Million	Feb. 05	MT
Valneva Sells Chikungunya Virus Vaccine’s Priority Review Voucher for $103 Million	Feb. 05	MT
Valneva: sale of priority review warrant for Ixchiq	Feb. 05	CF
Valneva: Grimaud holds less than 10% of the capital	Jan. 15	CF
Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva?S Single-Shot Chikungunya Vaccine	Jan. 10	CI

Chart Valneva

Duration

Period

More charts

Company Profile

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Ratings for Valneva

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.444 EUR

Average target price

8.95 EUR

Spread / Average Target

+159.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VALNEVA	-26.57%	510M
IQVIA HOLDINGS INC.	+2.17%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.23%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+6.56%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.92%	18.12B
MEDPACE HOLDINGS, INC.	+30.28%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.23%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.99%	11B

Other Biotechnology & Medical Research